Skip to content

Clinical trials

Observational Pulmonary Disease, Chronic Obstructive trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Phase: Observational Country / region: United States Clear all

236 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20021
20032
20044
20058
200612
200714
20089
20098
201010
20118
20128
201314
201416
20158
20168
201712
201811
201910
202013
202119
20228
20235
20245
202514
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed152
Recruiting26
Terminated21
Unknown status18
Active, not recruiting8
Enrolling by invitation6
Withdrawn5

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Weill Medical College of Cornell University15
Brigham and Women's Hospital12
University of Pittsburgh10
University of Michigan9
AstraZeneca8
Boehringer Ingelheim7
GlaxoSmithKline7
Washington University School of Medicine6
Columbia University4
Johns Hopkins University4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive236
Emphysema37
Asthma34
Heart Failure19
Lung Diseases19
Bronchitis, Chronic18
Diabetes Mellitus14
Dyspnea11
Lung Diseases, Interstitial9
Pneumonia9

Trials

Showing 1 to 25 of 236. Each trial links to its page on Pharma Observatory.

136 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.